{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T01:41:40Z","timestamp":1792460500014,"version":"4.5.0"},"reference-count":73,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,3,1]],"date-time":"2020-03-01T00:00:00Z","timestamp":1583020800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,3,1]],"date-time":"2020-03-01T00:00:00Z","timestamp":1583020800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100000038","name":"Natural Sciences and Engineering Research Council of Canada","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000038","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000156","name":"Fonds de Recherche du Qu\u00e9bec - Sant\u00e9","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000156","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000864","name":"Michael J. Fox Foundation for Parkinson's Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000864","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100012479","name":"Weston Brain Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100012479","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100009307","name":"Parkinson Canada","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100009307","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmacology"],"published-print":{"date-parts":[[2020,3]]},"DOI":"10.1016\/j.ejphar.2020.172914","type":"journal-article","created":{"date-parts":[[2020,1,8]],"date-time":"2020-01-08T16:18:46Z","timestamp":1578500326000},"page":"172914","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":23,"special_numbering":"C","title":["Ondansetron, a highly selective 5-HT3 receptor antagonist, reduces L-DOPA-induced dyskinesia in the 6-OHDA-lesioned rat model of Parkinson's disease"],"prefix":"10.1016","volume":"871","author":[{"given":"Cynthia","family":"Kwan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Imane","family":"Frouni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominique","family":"B\u00e9dard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adjia","family":"Hamadjida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Huot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejphar.2020.172914_bib1","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1136\/jnnp-2014-308119","article-title":"Neuropsychological changes following deep brain stimulation surgery for Parkinson's disease: comparisons of treatment at pallidal and subthalamic targets versus best medical therapy. Journal of Neurology","volume":"86","author":"Rothlind","year":"2015","journal-title":"Neurosurgery & Psychiatry"},{"key":"10.1016\/j.ejphar.2020.172914_bib2","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.ibror.2018.12.001","article-title":"Anti-dyskinetic efficacy of 5-HT3 receptor antagonist in the hemi-parkinsonian rat model","volume":"6","author":"Aboulghasemi","year":"2018","journal-title":"IBRO Rep"},{"key":"10.1016\/j.ejphar.2020.172914_bib3","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/0014-2999(93)90282-M","article-title":"SR 57227A: a potent and selective agonist at central and peripheral 5-HT3 receptors in vitro and in vivo","volume":"237","author":"Bachy","year":"1993","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.ejphar.2020.172914_bib4","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1007\/BF00164581","article-title":"Dopamine releasing effect of phenylbiguanide in rat striatal slices","volume":"345","author":"Benuck","year":"1992","journal-title":"Naunyn Schmiedeberg's Arch. Pharmacol."},{"key":"10.1016\/j.ejphar.2020.172914_bib5","doi-asserted-by":"crossref","first-page":"1829","DOI":"10.1212\/WNL.57.10.1829","article-title":"Serotonin 5-HT1A agonist improves motor complications in rodent and primate parkinsonian models","volume":"57","author":"Bibbiani","year":"2001","journal-title":"Neurology"},{"key":"10.1016\/j.ejphar.2020.172914_bib6","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/0014-2999(88)90528-6","article-title":"Activation of a 5-HT3 receptor releases dopamine from rat striatal slice","volume":"155","author":"Blandina","year":"1988","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.ejphar.2020.172914_bib7","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1016\/S0022-3565(25)21081-3","article-title":"Release of endogenous dopamine by stimulation of 5-hydroxytryptamine3 receptors in rat striatum","volume":"251","author":"Blandina","year":"1989","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.ejphar.2020.172914_bib8","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1046\/j.1471-4159.1995.65010104.x","article-title":"Allosteric interactions among agonists and antagonists at 5-hydroxytryptamine3 receptors","volume":"65","author":"Bonhaus","year":"1995","journal-title":"J. Neurochem."},{"key":"10.1016\/j.ejphar.2020.172914_bib9","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1159\/000227176","article-title":"Global experience with ondansetron and future potential","volume":"50","author":"Butcher","year":"1993","journal-title":"Oncology"},{"key":"10.1016\/j.ejphar.2020.172914_bib10","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.1093\/brain\/awm082","article-title":"Dopamine released from 5-HT terminals is the cause of L-DOPA-induced dyskinesia in parkinsonian rats","volume":"130","author":"Carta","year":"2007","journal-title":"Brain"},{"key":"10.1016\/j.ejphar.2020.172914_bib11","article-title":"Ratings of L-DOPA-induced dyskinesia in the unilateral 6-OHDA lesion model of Parkinson's disease in rats and mice","volume":"9","author":"Cenci","year":"2007","journal-title":"Curr Protoc Neurosci Chapter"},{"key":"10.1016\/j.ejphar.2020.172914_bib12","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/j.neuroscience.2019.04.008","article-title":"Effects of muscarinic acetylcholine m1 and m4 receptor blockade on dyskinesia in the hemi-parkinsonian rat","volume":"409","author":"Chambers","year":"2019","journal-title":"Neuroscience"},{"key":"10.1016\/j.ejphar.2020.172914_bib13","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1111\/j.1476-5381.1987.tb11394.x","article-title":"Effects of the 5-HT3 receptor antagonist, GR38032F, on raised dopaminergic activity in the mesolimbic system of the rat and marmoset brain","volume":"92","author":"Costall","year":"1987","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.ejphar.2020.172914_bib14","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1097\/00001756-199009000-00021","article-title":"5-HT3 receptor antagonists attenuate dopamine-induced hyperactivity in the rat","volume":"1","author":"Costall","year":"1990","journal-title":"Neuroreport"},{"key":"10.1016\/j.ejphar.2020.172914_bib15","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/S0165-6147(02)02017-5","article-title":"Assessing antidepressant activity in rodents: recent developments and future needs","volume":"23","author":"Cryan","year":"2002","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.ejphar.2020.172914_bib16","doi-asserted-by":"crossref","first-page":"6528","DOI":"10.1523\/JNEUROSCI.18-16-06528.1998","article-title":"Opposite change of in vivo dopamine release in the rat nucleus accumbens and striatum that follows electrical stimulation of dorsal raphe nucleus: role of 5-HT3 receptors","volume":"18","author":"De Deurwaerdere","year":"1998","journal-title":"J. Neurosci."},{"key":"10.1016\/j.ejphar.2020.172914_bib17","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1016\/S1474-4422(06)70471-9","article-title":"Epidemiology of Parkinson's disease","volume":"5","author":"de Lau","year":"2006","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.ejphar.2020.172914_bib18","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.bbr.2007.01.013","article-title":"Modulation of L-DOPA-induced abnormal involuntary movements by clinically tested compounds: further validation of the rat dyskinesia model","volume":"179","author":"Dekundy","year":"2007","journal-title":"Behav. Brain Res."},{"key":"10.1016\/j.ejphar.2020.172914_bib19","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/S0079-6123(08)00921-7","article-title":"Serotonin modulation of the basal ganglia circuitry: therapeutic implication for Parkinson's disease and other motor disorders","volume":"172","author":"Di Matteo","year":"2008","journal-title":"Prog. Brain Res."},{"key":"10.1016\/j.ejphar.2020.172914_bib71","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1093\/clinchem\/45.10.1813","article-title":"Human pharmacokinetics of L-3,4-dihydroxyphenylalanine studied with microdialysis","volume":"10","author":"Dizdar","year":"1999","journal-title":"Clin. Chem."},{"key":"10.1016\/j.ejphar.2020.172914_bib20","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1038\/sj.mp.4001314","article-title":"Antidepressants are functional antagonists at the serotonin type 3 (5-HT3) receptor","volume":"8","author":"Eisensamer","year":"2003","journal-title":"Mol. Psychiatry"},{"key":"10.1016\/j.ejphar.2020.172914_bib500","doi-asserted-by":"crossref","first-page":"8","DOI":"10.6030\/1939-067X-3.1.8","article-title":"Clinical trial structures","volume":"3","author":"Evans","year":"1999","journal-title":"J. Exp. Stroke Transl. Med."},{"key":"10.1016\/j.ejphar.2020.172914_bib21","first-page":"280","article-title":"Parkinson Psychosis Rating Scale: a practical instrument for grading psychosis in Parkinson's disease","volume":"21","author":"Friedberg","year":"1998","journal-title":"Clin. Neuropharmacol."},{"key":"10.1016\/j.ejphar.2020.172914_bib23","doi-asserted-by":"crossref","first-page":"107725","DOI":"10.1016\/j.neuropharm.2019.107725","article-title":"Activation of mGlu 2\/3 receptors, a novel therapeutic approach to alleviate dyskinesia and psychosis in experimental parkinsonism","volume":"158","author":"Frouni","year":"2019","journal-title":"Neuropharmacology"},{"issue":"1","key":"10.1016\/j.ejphar.2020.172914_bib22","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1007\/s00221-018-5390-4","article-title":"Effect of the selective 5-HT2A receptor antagonist EMD-281,014 on L-DOPA-induced abnormal involuntary movements in the 6-OHDA-lesioned rat","volume":"237","author":"Frouni","year":"2019","journal-title":"Exp. Brain Res."},{"key":"10.1016\/j.ejphar.2020.172914_bib24","doi-asserted-by":"crossref","first-page":"112766","DOI":"10.1016\/j.jpba.2019.07.014","article-title":"Highly sensitive HPLC-MS\/MS assay for the quantitation of ondansetron in rat plasma and rat brain tissue homogenate following administration of a very low subcutaneous dose","volume":"175","author":"Gaudette","year":"2019","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.ejphar.2020.172914_bib25","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/0006-8993(91)90242-N","article-title":"Localization of 5-HT3 receptors in the rat brain using [3H]LY278584","volume":"553","author":"Gehlert","year":"1991","journal-title":"Brain Res."},{"key":"10.1016\/j.ejphar.2020.172914_bib26","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0014-2999(96)00028-3","article-title":"Effects of 5-HT3 receptor-selective agents on locomotor activity in rats following injection into the nucleus accumbens and the ventral tegmental area","volume":"303","author":"Gillies","year":"1996","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.ejphar.2020.172914_bib27","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/0014-2999(90)90638-M","article-title":"Effects of the 5-HT3 antagonist GR38032F (ondansetron) on benzodiazepine withdrawal in rats","volume":"185","author":"Goudie","year":"1990","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.ejphar.2020.172914_bib28","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1056\/NEJMoa000827","article-title":"Deep-brain stimulation of the subthalamic nucleus or the pars interna of the globus pallidus in Parkinson's disease","volume":"345","year":"2001","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejphar.2020.172914_bib29","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.neuropharm.2018.06.038","article-title":"The highly selective 5-HT2A antagonist EMD-281,014 reduces dyskinesia and psychosis in the L-DOPA-treated parkinsonian marmoset","volume":"139","author":"Hamadjida","year":"2018","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.ejphar.2020.172914_bib30","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1097\/FBP.0000000000000441","article-title":"Classic animal models of Parkinson's disease: a historical perspective","volume":"30","author":"Hamadjida","year":"2019","journal-title":"Behav. Pharmacol."},{"key":"10.1016\/j.ejphar.2020.172914_bib72","first-page":"813","article-title":"Preladenant in patients with Parkinson\u2019s disease and motor fluctuations: a phase 2, double-blind, randomised trial","volume":"3","author":"Hauser","year":"2011","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.ejphar.2020.172914_bib31","doi-asserted-by":"crossref","first-page":"511","DOI":"10.3233\/JPD-171134","article-title":"ADS-5102 (amantadine) extended-release capsules for levodopa-induced dyskinesia in Parkinson's disease (EASE LID 2 study): interim results of an open-label safety study","volume":"7","author":"Hauser","year":"2017","journal-title":"J. Parkinson's Dis."},{"key":"10.1016\/j.ejphar.2020.172914_bib32","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1136\/jnnp.67.3.300","article-title":"The sydney multicentre study of Parkinson's disease: progression and mortality at 10 years","volume":"67","author":"Hely","year":"1999","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.ejphar.2020.172914_bib33","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1002\/mds.20324","article-title":"Sydney Multicenter Study of Parkinson's disease: non-L-dopa-responsive problems dominate at 15 years","volume":"20","author":"Hely","year":"2005","journal-title":"Mov. Disord."},{"key":"10.1016\/j.ejphar.2020.172914_bib34","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1038\/sj.bjp.0703687","article-title":"Involvement of 5-HT(3) receptors in the nucleus accumbens in the potentiation of cocaine-induced behaviours in the rat","volume":"131","author":"Herges","year":"2000","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.ejphar.2020.172914_bib35","first-page":"371","article-title":"Serotonin 5-HT3, 5-HT4, and 5-HT-M receptors","volume":"3","author":"Hoyer","year":"1990","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.ejphar.2020.172914_bib70","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1016\/j.neuropharm.2012.06.012","article-title":"L-DOPA pharmacokinetics in the MPTP-lesioned macaque model of Parkinson\u2019s disease","volume":"63","author":"Huot","year":"2012","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.ejphar.2020.172914_bib36","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1007\/s00221-013-3621-2","article-title":"The serotonergic system in motor and non-motor manifestations of Parkinson's disease","volume":"230","author":"Huot","year":"2013","journal-title":"Exp. Brain Res."},{"key":"10.1016\/j.ejphar.2020.172914_bib37","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1097\/FBP.0000000000000096","article-title":"L-745,870 reduces the expression of abnormal involuntary movements in the 6-OHDA-lesioned rat","volume":"26","author":"Huot","year":"2015","journal-title":"Behav. Pharmacol."},{"key":"10.1016\/j.ejphar.2020.172914_bib38","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1124\/jpet.106.110429","article-title":"In 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated primates, the selective 5-hydroxytryptamine 1a agonist (R)-(+)-8-OHDPAT inhibits levodopa-induced dyskinesia but only with increased motor disability","volume":"319","author":"Iravani","year":"2006","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.ejphar.2020.172914_bib39","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/0014-2999(89)90700-0","article-title":"Binding of the 5-HT3 ligand, [3H]GR65630, to rat area postrema, vagus nerve and the brains of several species","volume":"159","author":"Kilpatrick","year":"1989","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.ejphar.2020.172914_bib40","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.pbb.2015.11.009","article-title":"Involvement of N-methyl-d-aspartate receptors in the antidepressant-like effect of 5-hydroxytryptamine 3 antagonists in mouse forced swimming test and tail suspension test","volume":"141","author":"Kordjazy","year":"2016","journal-title":"Pharmacol. Biochem. Behav."},{"key":"10.1016\/j.ejphar.2020.172914_bib41","doi-asserted-by":"crossref","DOI":"10.1139\/cjpp-2019-0551","article-title":"Pharmacokinetic profile of the selective 5-HT3 receptor antagonist ondansetron in the rat: an original study and a mini-review of the literature","author":"Kwan","year":"2020","journal-title":"Can J. Physiol. Pharmacol."},{"key":"10.1016\/j.ejphar.2020.172914_bib42","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1007\/s00221-018-5434-9","article-title":"5-HT2A blockade for dyskinesia and psychosis in Parkinson's disease: is there a limit to the efficacy of this approach? A study in the MPTP-lesioned marmoset and a literature mini-review","volume":"237","author":"Kwan","year":"2019","journal-title":"Exp. Brain Res."},{"key":"10.1016\/j.ejphar.2020.172914_bib43","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1002\/syn.890100402","article-title":"Quantitative autoradiographic mapping of 5-HT3 receptors in the rat CNS using [125I]iodo-zacopride and [3H]zacopride as radioligands","volume":"10","author":"Laporte","year":"1992","journal-title":"Synapse (New York, N.Y.)"},{"key":"10.1016\/j.ejphar.2020.172914_bib44","doi-asserted-by":"crossref","first-page":"16005","DOI":"10.1038\/s41598-017-16228-1","article-title":"Levodopa-induced abnormal involuntary movements correlate with altered permeability of the blood-brain-barrier in the basal ganglia","volume":"7","author":"Lerner","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ejphar.2020.172914_bib45","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1046\/j.0953-816x.2001.01843.x","article-title":"Pharmacological validation of behavioural measures of akinesia and dyskinesia in a rat model of Parkinson's disease","volume":"15","author":"Lundblad","year":"2002","journal-title":"Eur. J. Neurosci."},{"key":"10.1016\/j.ejphar.2020.172914_bib46","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1056\/NEJM199003223221205","article-title":"Comparison of the 5-hydroxytryptamine3 (serotonin) antagonist ondansetron (gr 38032F) with high-dose metoclopramide in the control of cisplatin-induced emesis","volume":"322","author":"Marty","year":"1990","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejphar.2020.172914_bib47","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/j.tips.2005.05.002","article-title":"The 'magic' of L-dopa: why is it the gold standard Parkinson's disease therapy?","volume":"26","author":"Mercuri","year":"2005","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.ejphar.2020.172914_bib48","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/S0014-2999(01)00986-4","article-title":"Reversal of neuroleptic-induced orofacial dyskinesia by 5-HT3 receptor antagonists","volume":"420","author":"Naidu","year":"2001","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.ejphar.2020.172914_bib49","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.neuropharm.2014.07.004","article-title":"Structural plasticity of the brain to psychostimulant use","volume":"87","author":"Nyberg","year":"2014","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.ejphar.2020.172914_bib50","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.1002\/mds.27131","article-title":"Randomized, placebo-controlled trial of ADS-5102 (amantadine) extended-release capsules for levodopa-induced dyskinesia in Parkinson's disease (EASE LID 3)","volume":"32","author":"Oertel","year":"2017","journal-title":"Mov. Disord."},{"key":"10.1016\/j.ejphar.2020.172914_bib51","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1001\/jamaneurol.2017.3205","article-title":"ADS-5102 (amantadine) extended release for levodopa-induced dyskinesia","volume":"74","author":"Pahwa","year":"2017","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.ejphar.2020.172914_bib52","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1001\/jamaneurol.2017.0943","article-title":"ADS-5102 (amantadine) extended-release capsules for levodopa-induced dyskinesia in Parkinson disease (EASE LID study): a randomized clinical trial","volume":"74","author":"Pahwa","year":"2017","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.ejphar.2020.172914_bib53","doi-asserted-by":"crossref","first-page":"S60","DOI":"10.1007\/BF02245008","article-title":"Electrophysiological, biochemical and behavioral evidence for 5-HT2 and 5-HT3 mediated control of dopaminergic function","volume":"112","author":"Palfreyman","year":"1993","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.ejphar.2020.172914_bib54","series-title":"The Rat Brain in Stereotaxic Coordinates","author":"Paxinos","year":"2018"},{"key":"10.1016\/j.ejphar.2020.172914_bib55","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1046\/j.1460-9568.2003.02512.x","article-title":"Conditional involvement of striatal serotonin 3 receptors in the control of in vivo dopamine outflow in the rat striatum","volume":"17","author":"Porras","year":"2003","journal-title":"Eur. J. Neurosci."},{"key":"10.1016\/j.ejphar.2020.172914_bib56","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1097\/FBP.0b013e3282f3cfd4","article-title":"Antidepressant-like effects of serotonin type-3 antagonist, ondansetron: an investigation in behaviour-based rodent models","volume":"19","author":"Ramamoorthy","year":"2008","journal-title":"Behav. Pharmacol."},{"key":"10.1016\/j.ejphar.2020.172914_bib57","doi-asserted-by":"crossref","first-page":"255","DOI":"10.3233\/JPD-130186","article-title":"Levodopa in the treatment of Parkinson's disease: current status and new developments","volume":"3","author":"Salat","year":"2013","journal-title":"J. Parkinson's Dis."},{"key":"10.1016\/j.ejphar.2020.172914_bib58","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1016\/S0028-3908(00)00005-8","article-title":"CNS plasticity and assessment of forelimb sensorimotor outcome in unilateral rat models of stroke, cortical ablation, parkinsonism and spinal cord injury","volume":"39","author":"Schallert","year":"2000","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.ejphar.2020.172914_bib59","first-page":"355","article-title":"Effect of the 5-HT3 receptor antagonist ondansetron on amphetamine-induced hyperactivity and stereotypy in rats","volume":"44","author":"Shankar","year":"2000","journal-title":"Indian J. Physiol. Pharmacol."},{"key":"10.1016\/j.ejphar.2020.172914_bib60","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1038\/294475a0","article-title":"Persistent behavioural effect in apomorphine in 6-hydroxydopamine-lesioned rats","volume":"294","author":"Silverman","year":"1981","journal-title":"Nature"},{"key":"10.1016\/j.ejphar.2020.172914_bib61","first-page":"115","article-title":"5-HT3 receptor antagonists for the treatment of nausea\/vomiting","volume":"1","author":"Smith","year":"2012","journal-title":"Ann. Palliat. Med."},{"key":"10.1016\/j.ejphar.2020.172914_bib62","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/0014-2999(89)90402-0","article-title":"Effect of acute and chronic MDL 73,147EF, a 5-HT3 receptor antagonist, on A9 and A10 dopamine neurons","volume":"163","author":"Sorensen","year":"1989","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.ejphar.2020.172914_bib63","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1097\/00001756-199902250-00034","article-title":"Role of serotonergic neurons in L-DOPA-derived extracellular dopamine in the striatum of 6-OHDA-lesioned rats","volume":"10","author":"Tanaka","year":"1999","journal-title":"Neuroreport"},{"key":"10.1016\/j.ejphar.2020.172914_bib64","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1136\/pgmj.2006.054759","article-title":"Levodopa-induced dyskinesia in Parkinson's disease: clinical features, pathogenesis, prevention and treatment","volume":"83","author":"Thanvi","year":"2007","journal-title":"Postgrad. Med. J."},{"key":"10.1016\/j.ejphar.2020.172914_bib65","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1016\/0028-3908(94)90120-1","article-title":"Ondansetron, a selective 5-HT3 receptor antagonist, reduces palatable food consumption in the nondeprived rat","volume":"33","author":"van der Hoek","year":"1994","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.ejphar.2020.172914_bib66","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/0922-4106(90)90190-9","article-title":"The concept of selectivity in 5-HT receptor research","volume":"188","author":"van Wijngaarden","year":"1990","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.ejphar.2020.172914_bib67","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/S1474-4422(10)70093-4","article-title":"Deep brain stimulation plus best medical therapy versus best medical therapy alone for advanced Parkinson's disease (PD SURG trial): a randomised, open-label trial","volume":"9","author":"Williams","year":"2010","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.ejphar.2020.172914_bib68","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1111\/j.1476-5381.1994.tb17087.x","article-title":"Role of 5-HT3 receptors in basal and K(+)-evoked dopamine release from rat olfactory tubercle and striatal slices","volume":"113","author":"Zazpe","year":"1994","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.ejphar.2020.172914_bib69","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1212\/WNL.45.7.1305","article-title":"Psychosis in advanced Parkinson's disease: treatment with ondansetron, a 5-HT3 receptor antagonist","volume":"45","author":"Zoldan","year":"1995","journal-title":"Neurology"}],"container-title":["European Journal of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014299920300066?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014299920300066?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,15]],"date-time":"2025-09-15T22:33:40Z","timestamp":1757975620000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0014299920300066"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,3]]},"references-count":73,"alternative-id":["S0014299920300066"],"URL":"https:\/\/doi.org\/10.1016\/j.ejphar.2020.172914","relation":{},"ISSN":["0014-2999"],"issn-type":[{"value":"0014-2999","type":"print"}],"subject":[],"published":{"date-parts":[[2020,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Ondansetron, a highly selective 5-HT3 receptor antagonist, reduces L-DOPA-induced dyskinesia in the 6-OHDA-lesioned rat model of Parkinson's disease","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejphar.2020.172914","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"172914"}}